Cost-effective osteoporosis treatment thresholds in Greece
P Makras1, K Athanasakis, N Boubouchairopoulou
1Department of Endocrinology and Diabetes, 251 Hellenic Air Force General Hospital, Athens, Greece, makras@internet.gr.
Summary
Osteoporosis treatment is cost-effective in Greece for individuals under 75 with fracture risks of 2.5% (hip) and 10% (major). For older patients, these thresholds increase to 5% and 15% respectively, using the FRAX tool.
Area of Science:
- Health Economics
- Osteoporosis Management
- Public Health Policy
Background:
- Osteoporosis poses a significant public health challenge globally and in Greece.
- Identifying cost-effective intervention strategies is crucial for optimizing healthcare resource allocation.
- The FRAX tool provides fracture risk assessment, but its application for cost-effectiveness requires local calibration.
Purpose of the Study:
- To determine the fracture probability thresholds for cost-effective osteoporosis treatment in Greece.
- To adapt the FRAX (Fracture Risk Assessment Tool) algorithm for Greek healthcare economic evaluations.
- To establish age- and risk-stratified intervention guidelines based on cost-effectiveness.
Main Methods:
- A Greek-specific Markov cohort model was developed.
- Quality-Adjusted Life Years (QALYs) were utilized to assess cost-effectiveness.
- Intervention cost-effectiveness thresholds were calculated based on a willingness to pay of €30,000 per QALY gained.
Main Results:
- A biphasic intervention threshold model was identified.
- For individuals under 75, cost-effective treatment is indicated at 10-year hip fracture probability of ≥2.5% and major osteoporotic fracture probability of ≥10%.
- For individuals 75 and older, thresholds increase to ≥5% for hip and ≥15% for major osteoporotic fractures.
Conclusions:
- The FRAX algorithm can effectively identify candidates for cost-effective osteoporosis treatment in Greece.
- Implementing these age- and risk-stratified thresholds can optimize treatment decisions and resource allocation.
- This study provides evidence-based guidance for osteoporosis management in the Greek healthcare setting.
Related Concept Videos
Bone Disorders
8.7K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.7K
Osteoclasts in Bone Remodeling
4.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.9K
Bone Remodeling
41.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
41.3K

